WHO R&D ‘Demonstration Projects’: A Member State-driven step towards a sustainable global framework for neglected disease R&D

By Jean-François Alesandrini, Fundraising & Advocacy Director

WHO Member States and experts, after weeks of consultations, are in the process of selecting ‘demonstration projects’ to address the unmet medical needs of developing countries. The overall objective of this process is to evaluate and assess new innovative mechanisms to coordinate and fund public health research and development (R&D).

Best Science for the Most Neglected: Where Do We Stand 10 Years On?

4 - 5 December 2013
Institut Pasteur, Paris, France

You can still register for December 5th !

Register here !

Join DNDi and its founding partners, Institut Pasteur and MSF, in collaboration with PLOS, for a special scientific event culminating DNDi’s 10-year anniversary.

ASTMH 2013

13 - 17 November 2013
Whashington DC, United States

DNDi will organize a symposium on Chagas where the results of the E1224 Phase 2 study will be released. A side event on R&D for Chagas will also be co-organized with PAHO and two scientific posters on malaria and HAT will be presented.

Persistent ‘fatal imbalance’ in new drug development for neglected diseases

About a decade after the first study (2001) carried out by MSF and the Drugs for Neglected Diseases Working Group, the precursor to DNDi, that pointed out that only 1.1% of new drugs approved between 1975 and 1999 were found to be for neglected diseases, a new study was published in the open-access journal The Lancet Global Health. DNDi and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development (R&D) efforts. Of the 850 new drugs and vaccines approved for all diseases in 2000-2011, only 4% were for neglected diseases. This continued ‘fatal imbalance’ in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.

Read the press release in English
Read the press release in French
Read the article

MoU signed between DNDi, Medicines for Malaria Venture (MMV), and the Royal Society for Chemistry (RSC) to foster knowledge sharing on open source drug discovery

The MoU aims at collaborating in an effort to build a global community of researchers engaged in open source drug discovery with the common aim of developing online platforms, datasets, drug discovery software tools, and shared medicinal chemistry expertise that deliver new pharmaceutical therapies for the treatment of neglected tropical diseases.

Listen to Robert Don,
Discovery & Preclinical Director

DNDi featured in the documentary ‘The Pharmacy of Forgotten Patients’

‘The Pharmacy of Forgotten Patients’ (‘La Pharmacie des Malades Oubliés’ in French) explores the progress made recently by new initiatives, namely product development partnerships (PDPs), in Research & Development for neglected diseases. The French film director Gérard Lafont dedicates a large part of the film to DNDi’s activities and partnerships in the field of sleeping sickness and Chagas disease.

Watch the documentary in English
Watch the documentary in French
Filmmaker Gérard Lafont speaks about the documentary

Strategic agreement between Mundo Sano and DNDi for access to treatments for Chagas disease patients

The agreement aims to ensure crucial second source of pediatric formulation of benznidazole for millions of children in need of treatment.

DNDi on Swiss TV

Swiss television RTS produced for its show ‘Le court du jour’ a series on international cooperation professions with short portraits of people working in this field in Geneva. One of the portraits was dedicated to Dr Nathalie Strub-Wourgaft, Medical Director at DNDi (in French).

Watch the portrait of Dr. Nathalie Strub-Wourgaft

In memory of Dr Alleluia Muwanga

Dr Alleluia Muwanga passed away on 29 September 2013. He was 41. Alleluia was working as a dedicated and passionate investigator for the clinical trial on fexinidazole for sleeping sickness in Vanga Hospital in Democratic Republic of Congo. He is deeply missed by his family, friends, and colleagues.